- Home
- STOK vs AUPH Comparison
STOK vs AUPH Comparison
Compare STOK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- AUPH
- Stock Information
- Founded
- STOK 2014
- AUPH 1993
- Country
- STOK United States
- AUPH Canada
- Employees
- STOK N/A
- AUPH N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- STOK Health Care
- AUPH Health Care
- Exchange
- STOK Nasdaq
- AUPH Nasdaq
- Market Cap
- STOK 1.3B
- AUPH 1.4B
- IPO Year
- STOK 2019
- AUPH 1999
- Fundamental
- Price
- STOK $22.74
- AUPH $12.30
- Analyst Decision
- STOK Strong Buy
- AUPH Strong Buy
- Analyst Count
- STOK 6
- AUPH 3
- Target Price
- STOK $26.60
- AUPH $12.00
- AVG Volume (30 Days)
- STOK 893.3K
- AUPH 1.5M
- Earning Date
- STOK 11-04-2025
- AUPH 11-06-2025
- Dividend Yield
- STOK N/A
- AUPH N/A
- EPS Growth
- STOK N/A
- AUPH N/A
- EPS
- STOK 0.91
- AUPH 0.42
- Revenue
- STOK $199,893,000.00
- AUPH $260,111,000.00
- Revenue This Year
- STOK $416.54
- AUPH $16.92
- Revenue Next Year
- STOK N/A
- AUPH $14.43
- P/E Ratio
- STOK $25.02
- AUPH $29.12
- Revenue Growth
- STOK 1218.82
- AUPH 25.59
- 52 Week Low
- STOK $5.35
- AUPH $6.55
- 52 Week High
- STOK $24.60
- AUPH $12.90
- Technical
- Relative Strength Index (RSI)
- STOK 73.55
- AUPH 56.77
- Support Level
- STOK $18.80
- AUPH $12.06
- Resistance Level
- STOK $24.60
- AUPH $12.90
- Average True Range (ATR)
- STOK 1.23
- AUPH 0.39
- MACD
- STOK 0.02
- AUPH -0.08
- Stochastic Oscillator
- STOK 67.93
- AUPH 54.89
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.